Yahoo Finance: New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness and tolerability in a real-world patient population, ... New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting Please provide your email address to receive an email when new articles are posted on . Depressive symptoms improved within 24 hours of the first dose of esketamine nasal spray.
Common adverse effects ... The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images. Hundreds of millions of ...
esketamine nasal spray, The American Journal of Managed Care: Esketamine Nasal Spray Shows Rapid, Durable Effectiveness in Treatment-Resistant Depression New real-world evidence on esketamine (Spravato; Janssen Pharmaceutical) nasal spray is reinforcing its role as an effective and durable treatment option for adults with treatment-resistant depression ... The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in adults ... Houston Public Media: FDA allows standalone use of nasal spray antidepressant Spravato (esketamine) The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression.
